| Summary: | Justin W Ady, Jacqueline Heffner, Elizabeth Klein, Yuman Fong Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Abstract: The development of targeted agents and chemotherapies for pancreatic cancer has only modestly affected clinical outcome and not changed 5-year survival. Fortunately the genetic and molecular mechanisms underlying pancreatic cancer are being rapidly uncovered and are providing opportunities for novel targeted therapies. Oncolytic viral therapy is one of the most promising targeted agents for pancreatic cancer. This review will look at the current state of the development of these self-replicating nanoparticles in the treatment of pancreatic cancer. Keywords: pancreatic cancer, oncolytic virus, review
|
|---|
